Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 12,561 | $2.16 | $27,131.76 | 216,358Direct | Form 4 filed 30 Sep 2026, on sec.gov (opens in a new tab)Filed 30 Sep 2026 | |
| Higuchi John W. | Director | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 40,000 | $2.03 | $81,200 | 203,797Direct | Form 4 filed 7 Apr 2026, on sec.gov (opens in a new tab)Filed 7 Apr 2026 | |
| Patel Mahesh V. | Director, Chief Executive Officer | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 25,000 | $2.03 | $50,750 | 160,679Direct | Form 4 filed 6 Apr 2026, on sec.gov (opens in a new tab)Filed 6 Apr 2026 | |
| Higuchi John W. | Director | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 123,000 | $2.05 | $252,150 | 163,797Direct | Form 4 filed 6 Apr 2026, on sec.gov (opens in a new tab)Filed 6 Apr 2026 | |
| Patel Mahesh V. | Director, Chief Executive Officer | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 25,000 | $2.02 | $50,500 | 135,679Direct | Form 4 filed 2 Apr 2026, on sec.gov (opens in a new tab)Filed 2 Apr 2026 | |
| Fogarty Krista | Principal Accounting Officer | Lipocine Inc.LPCN | OtherA · Grant or award from the company | 991 | $0.00 | $0 | 1,727Direct | Form 4 filed 12 Mar 2024, on sec.gov (opens in a new tab)Filed 12 Mar 2024 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | OtherA · Grant or award from the company | 4,893 | $0.00 | $0 | 112,311Direct | Form 4 filed 12 Mar 2024, on sec.gov (opens in a new tab)Filed 12 Mar 2024 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 8,706 | $5.03 | $43,791.18 | 107,418Direct | Form 4 filed 25 May 2023, on sec.gov (opens in a new tab)Filed 25 May 2023 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 150,000 | $0.32 | $48,000 | 1,678,090Direct | Form 4 filed 24 Mar 2023, on sec.gov (opens in a new tab)Filed 24 Mar 2023 | |
| Ono Richard Dana | Director | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 4,000 | $0.34 | $1,360 | 14,125Direct | Form 4 filed 20 Mar 2023, on sec.gov (opens in a new tab)Filed 20 Mar 2023 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 50,000 | $0.33 | $16,500 | 1,528,090Direct | Form 4 filed 17 Mar 2023, on sec.gov (opens in a new tab)Filed 17 Mar 2023 | |
| Papapetropoulos Spyros | Director | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 21,739 | $0.47 | $10,217.33 | 21,739Direct | Form 4 filed 28 Nov 2022, on sec.gov (opens in a new tab)Filed 28 Nov 2022 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 75,000 | $0.39 | $29,250 | 1,478,090Direct | Form 4 filed 14 Nov 2022, on sec.gov (opens in a new tab)Filed 14 Nov 2022 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 100,000 | $0.41 | $41,000 | 1,403,090Direct | Form 4 filed 27 Sep 2022, on sec.gov (opens in a new tab)Filed 27 Sep 2022 | |
| Fogarty Krista | Principal Accounting Officer | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 12,500 | $0.86 | $10,750 | 12,500Direct | Form 4 filed 17 May 2022, on sec.gov (opens in a new tab)Filed 17 May 2022 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 50,000 | $0.77 | $38,500 | 1,303,090Direct | Form 4 filed 16 May 2022, on sec.gov (opens in a new tab)Filed 16 May 2022 | |
| Patel Mahesh V. | Director, CEO and President | Lipocine Inc.LPCN | BuyP · Open-market or private purchase | 25,000 | $1.09 | $27,250 | 1,253,090Direct | Form 4 filed 18 Nov 2021, on sec.gov (opens in a new tab)Filed 18 Nov 2021 | |
| Higuchi John W. | Director | Lipocine Inc.LPCN | SellS · Open-market or private sale | 5,000 | $1.35 | $6,750 | 693,548Direct | Form 4 filed 4 Jan 2021, on sec.gov (opens in a new tab)Filed 4 Jan 2021 | |
| Higuchi John W. | Director | Lipocine Inc.LPCN | SellS · Open-market or private sale | 1,700 | $1.35 | $2,295 | 698,548Direct | Form 4 filed 4 Jan 2021, on sec.gov (opens in a new tab)Filed 4 Jan 2021 | |
| HILL STEPHEN A | Director | Lipocine Inc.LPCN | OtherM · Option or derivative exercised or converted | 7,500 | $0.00 | $0 | 12,750Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 | |
| Higuchi John W. | Director | Lipocine Inc.LPCN | OtherM · Option or derivative exercised or converted | 3,750 | $0.00 | $0 | 700,248Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 | |
| Fink Jeffrey Arvin | Director | Lipocine Inc.LPCN | OtherM · Option or derivative exercised or converted | 5,625 | $0.00 | $0 | 6,562Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 | |
| BROWN MORGAN R | EVP and CFO | Lipocine Inc.LPCN | SellS · Open-market or private sale | 8,437 | $1.35 | $11,389.95 | 194,504Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 | |
| BROWN MORGAN R | EVP and CFO | Lipocine Inc.LPCN | OtherM · Option or derivative exercised or converted | 28,125 | $0.00 | $0 | 202,941Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 | |
| Patel Mahesh V. | Director, Chief Executive Officer | Lipocine Inc.LPCN | SellS · Open-market or private sale | 15,000 | $1.35 | $20,250 | 1,228,090Direct | Form 4 filed 17 Dec 2020, on sec.gov (opens in a new tab)Filed 17 Dec 2020 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.